Microarray analysis in gastric cancer: A review

被引:38
作者
D'Angelo, Giovanna [1 ]
Di Rienzo, Teresa [1 ]
Ojetti, Veronica [1 ]
机构
[1] Catholic Univ, Dept Internal Med & Gastroenterol, I-00168 Rome, Italy
关键词
Array; Gastric cancer; Prognosis; Genes; Chemotherapy; HELICOBACTER-PYLORI INFECTION; GENE-EXPRESSION PATTERNS; CARCINOEMBRYONIC ANTIGEN; CDNA-MICROARRAY; RISK-FACTORS; CA; 72-4; CARCINOMA; CLASSIFICATION; EPIDEMIOLOGY; PROGRESSION;
D O I
10.3748/wjg.v20.i34.11972
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Gastric cancer is one of the most common tumors worldwide. Although several treatment options have been developed, the mortality rate is increasing. Lymph node involvement is considered the most reliable prognostic indicator in gastric cancer. Early diagnosis improves the survival rate of patients and increases the likelihood of successful treatment. The most reliable diagnostic method is endoscopic examination, however, it is expensive and not feasible in poorer countries. Therefore, many innovative techniques have been studied to develop a new non-invasive screening test and to identify specific serum biomarkers. DNA microarray analysis is one of the new technologies able to measure the expression levels of a large number of genes simultaneously. It is possible to define the gene expression profile of the tumor and to correlate it with the prognosis and metastasis formation. Several studies in the literature have been published on the role of microarray analysis in gastric cancer and the mechanisms of proliferation and metastasis formation. The aim of this review is to analyze the importance of microarray analysis and its clinical applications to better define the genetic characteristics of gastric cancer and its possible implications in a more decisive treatment. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:11972 / 11976
页数:5
相关论文
共 39 条
[1]
Arnold M, 2013, EUR J CANCER, DOI [10.1016/j.ejca.2013.09.002, DOI 10.1016/J.EJCA.2013.09.002]
[2]
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[3]
Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833
[4]
Cho JY, 2013, J GASTRIC CANC, V13, P129
[5]
Pathogenesis of Helicobacter pylori Infection [J].
Cid, Trinidad Parra ;
Calvino Fernandez, Miryam ;
Benito-Martinez, Selma ;
Jones, Nicola L. .
HELICOBACTER, 2013, 18 :12-17
[6]
Corso G, 2012, ANN ITAL CHIR, V83, P172
[7]
Diet, microbial virulence, and Helicobacter pylori-induced gastric cancer [J].
Cover, Timothy L. ;
Peek, Richard M., Jr. .
GUT MICROBES, 2013, 4 (06) :482-493
[8]
Epidemiology of gastric cancer [J].
Crew, Katherine D. ;
Neugut, Alfred I. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (03) :354-362
[9]
Gastric Cancer Epidemiology and Risk Factors [J].
de Martel, Catherine ;
Forman, David ;
Plummer, Martyn .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2013, 42 (02) :219-+
[10]
DeRisi J, 1996, NAT GENET, V14, P457